Aura Biosciences, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-11. Between them they name 3 people. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Amy Elazzouzi, Senior Vice President, Finance, effective 2026-09-02
Appointment of Interim Principal Financial Officer In connection with Mr. Gibney's departure, on August 6, 2026, the Board appointed Amy Elazzouzi as the Company's Senior Vice President, Finance, Treasurer and Secretary, effective as of September 2, 2026 (the "Elazzouzi Effective Date").
Appointed: Amy Elazzouzi, Chief Financial Officer
In addition, the Board confirmed that, effective as of the Elazzouzi Effective Date, Ms. Elazzouzi will serve as the Company's interim principal financial officer until such time as the Board appoints a Chief Financial Officer of the Company.
Appointed: Jeremy Bender, Director, effective 2026-07-07
On July 3, 2026, the Board of Directors (the "Board") of Aura Biosciences, Inc. (the "Company") increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026 (the "Effective Date"), to fill the newly created vacancy.
Appointed: Natalie Holles, Chief Executive Officer, effective 2026-04-30
On April 29, 2026, the Board of Directors (the "Board") of Aura Biosciences, Inc. (the "Company") appointed Natalie Holles as the Company's Chief Executive Officer and President and as a Class I director with a term expiring at the Company's 2028 annual meeting of stockholders, effective as of April 30, 2026 (the "Effective Date").
Find people with the same kind of experience as the Senior Vice President, Finance at Aura Biosciences, Inc., with the record behind each one.
Find candidates like Finance at Aura Biosciences, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Aura Biosciences, Inc. is in the news or changes leadership.
Get an alert when Aura Biosciences, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Aura Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.